Key facts
- This page summarizes Robert Ticktin's Form 4 filing for PMV Pharmaceuticals, Inc. (PMVP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jul 2025, 19:51.
Robert Ticktin - 01 Jul 2025 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)
- Reporting relationship
- General Counsel & COO
- Issuer ticker
- PMVP
- Reported as of
- 01 Jul 2025
- Net transaction value
- -$24,651
- SEC form
- 4
- Accepted by SEC
- 03 Jul 2025, 19:51:53 UTC
- Prior SEC filing
- 23 Apr 2025
- Next SEC filing
- 09 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Ticktin
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Ticktin filed Form 4 for PMV Pharmaceuticals, Inc. (PMVP) on 03 Jul 2025.
Change
- Previous filing in this sequence was filed on 23 Apr 2025.
- Current net transaction value: -$24,651.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001613482
Primary reporting owner
Ticktin Robert
- Relationship
- General Counsel & COO
- Address
- C/O PMV PHARMACEUTICALS, INC., 400 ALEXANDER PARK DRIVE, SUITE 301, PRINCETON
- Signature
- /s/ Robert Ticktin
- Signature date
- 03 Jul 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PMVP
transaction
Common Stock
Sale
- Transaction value
- $24,651
- Shares
- -23,151
- Change %
- -19%
- Price
- $1.06
- Shares after
- 98,695
- Date
- 01 Jul 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.
Footnote F2
Includes 15,528 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2025.